Among patients with hormone receptor-positive tumours, 15-year OS was 72% (95% CI: 66–77) in the FEC14 group and 70% (95% CI: 64–76) in the FEC21 group (HR = 0.98, 95% CI: 0.73–1.31, p = 0.94) (Fig. 3a); 15-year EFS was 42% (95% CI: 34–50) in the FEC14 group and 44% (95% CI: 36–52) in the FEC21 group (HR = 1.01, 95% CI: 0.79–1.29; p = 0.79) (Fig. 3b). Here, NR4A1 is linked to neoplasm.